MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-026-16210-z

Медицинская библиотека · BMC cancer · 2026

Beyond tumor burden: PET/CT-derived psoas muscle quality and survival outcomes in metastatic NSCLC patients treated with nivolumab.

Gulbagci Burcu, Kuçukarda Ahmet, Fenercioglu Ozge Erol, Nazaroglu Aziz, Engin Esra Ozen, Divriklioglu Didem, Aslan Aygün, Ilce Huri Tilla, Yavuz Hatice, Akdag Fatma, Gokyer Ali, Yuce Elif, Korkmaz Kara Ulkü

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Reliable host-related biomarkers for prognostic outcomes in immunotherapy non-small cell lung cancer (NSCLC) remain limited. Although sarcopenia has been associated with poor prognosis, the relative contributions of muscle quantity, muscle quality, and muscle metabolic activity during immune checkpoint inhibitor (ICI) therapy are unclear. This study evaluated PET/CT-derived psoas muscle parameters as host-related prognostic biomarkers in metastatic NSCLC patients treated with nivolumab.

METHODS

In this multicenter retrospective study, 172 stage IV NSCLC patients receiving second-line nivolumab monotherapy were analyzed. Baseline PET/CT scans were used to assess tumor metabolic burden and psoas muscle characteristics. Muscle quantity was defined by psoas muscle index, muscle quality by mean Hounsfield unit (HU) attenuation, and muscle metabolic activity by SUVmax and SUVmean. Factors associated with progression-free survival (PFS) and overall survival (OS) were analyzed using univariable and multivariable Cox proportional hazards regression models.

RESULTS

In the overall cohort, median PFS and OS were 3.7 and 10.9 months, respectively. In multivariable analysis, psoas muscle HUmean was independently associated with OS (HR 0.959, 95% CI 0.931-0.988, p = 0.005), whereas PET-derived muscle metabolic parameters did not retain independent prognostic significance. Lower Programmed Death-Ligand 1 (PD-L1) expression (< 1%) (p = 0.019), higher total tumor metabolic volume (p = 0.025), and lower Advanced Lung Cancer Inflammation Index (ALI) scores (p = 0.038) were also independently associated with worse OS. Although patients with sarcopenia demonstrated shorter OS, sarcopenia based solely on muscle quantity was not independently associated with survival outcomes in multivariable analysis.

CONCLUSIONS

Imaging-derived muscle quality assessed on routine PET/CT was independently associated with survival in metastatic NSCLC patients receiving nivolumab. Radiologic muscle attenuation, together with systemic host-related factors, may improve prognostic stratification beyond tumor burden alone.

Для цитирования: Gulbagci Burcu, Kuçukarda Ahmet, Fenercioglu Ozge Erol, Nazaroglu Aziz, Engin Esra Ozen, Divriklioglu Didem, Aslan Aygün, Ilce Huri Tilla, Yavuz Hatice, Akdag Fatma, Gokyer Ali, Yuce Elif, Korkmaz Kara Ulkü. Beyond tumor burden: PET/CT-derived psoas muscle quality and survival outcomes in metastatic NSCLC patients treated with nivolumab.. BMC cancer. 2026. DOI: 10.1186/s12885-026-16210-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.